Protara Therapeutics (TARA) Operating Income (2013 - 2026)

Protara Therapeutics' Operating Income history runs 14 years deep, the most recent figure standing at -$19.6 million for Q1 2026.

• In Q1 2026, Operating Income fell 38.98% year-over-year to -$19.6 million; the TTM figure through Mar 2026 stood at -$70.1 million (down 36.22% YoY), while the FY2025 annual figure was -$64.5 million, down 31.32% from the prior year.
• Operating Income was -$19.6 million for Q1 2026 at Protara Therapeutics, down from -$19.1 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$8.0 million in Q3 2022 to a low of -$39.5 million in Q4 2022.
• Historically, Operating Income has averaged -$14.4 million across 5 years, with a median of -$12.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Operating Income tumbled 284.07% in 2022, then surged 72.05% in 2023.
• A 5-year view of Operating Income shows it stood at -$39.5 million in 2022, then soared by 72.05% to -$11.0 million in 2023, then fell by 29.63% to -$14.3 million in 2024, then plunged by 33.31% to -$19.1 million in 2025, then decreased by 2.88% to -$19.6 million in 2026.
• The last three Operating Income figures came in at -$19.6 million (Q1 2026), -$19.1 million (Q4 2025), and -$14.8 million (Q3 2025), per Business Quant data.